---
layout: use-case
title: "Autonomous Adverse Event Report Processing in Pharmacovigilance"
uc_id: "UC-050"
category: "Industry-Specific"
category_dir: "industry-specific"
category_icon: "briefcase"
industry: "Pharmaceutical / Life Sciences"
complexity: "High"
status: "detailed"
summary: "Agentic AI system that autonomously handles end-to-end ICSR processing from intake through submission-ready case with human-in-the-loop oversight for serious cases and causality assessment."
slug: "uc-050-pharma-adverse-event-processing"
has_solution_design: true
has_implementation_guide: true
has_evaluation: true
has_references: true
permalink: /use-cases/uc-050-pharma-adverse-event-processing/
---

## Problem Statement

Pharmaceutical companies are legally required to collect, assess, and submit Individual Case Safety Reports (ICSRs) for every adverse drug reaction reported against their products. The FDA's FAERS database alone contains over 31 million report entries, with approximately 700,000 new adverse event reports filed annually in the US. Each ICSR requires a trained pharmacovigilance specialist to manually extract data from unstructured sources, code medical terms to MedDRA dictionaries, assess causality, write a clinical narrative, and submit the case electronically — all within strict regulatory deadlines (7 days for fatal/life-threatening events, 15 days for other serious events).

A single routine case takes 2–4 hours of specialist time from intake through submission. Large pharma companies employ thousands of full-time pharmacovigilance staff globally, with per-product safety data management averaging $686K/year. Despite this investment, the manual process is error-prone and struggles to scale with growing report volumes.

## Business Impact

| Dimension | Description |
|-----------|-------------|
| **Cost** | Per-product PV data management averages ~$686K/year. ICSR processing staff cost $38–$163/hr (median $44.20/hr). A mid-size CRO like ProPharma processes 2,000+ ICSRs/month. |
| **Time** | 2–4 hours per routine ICSR. Serious/fatal cases require 7-day turnaround; other serious events require 15-day submission. |
| **Error Rate** | Manual MedDRA coding errors, missed duplicate reports, inconsistent causality assessments, and narrative quality issues are common. |
| **Scale** | ~700,000 AE reports/year in US alone. Large pharma handle tens of thousands of cases internally. |
| **Risk** | Late or inaccurate submissions trigger regulatory action. Missed safety signals can lead to patient harm and billion-dollar liability. |

## Desired Outcome

An agentic AI system that autonomously handles the end-to-end ICSR processing pipeline — from intake through submission-ready case — with human-in-the-loop oversight for serious cases and causality assessment. The system should process routine, non-serious cases with minimal human intervention ("touchless" processing) while flagging complex, serious, or ambiguous cases for expert review.

### Success Criteria

| Metric | Target |
|--------|--------|
| Processing time per case | < 30 minutes for routine cases (from 2–4 hours) |
| Manual effort reduction | 50–65% reduction in specialist FTE hours |
| Data accuracy at intake | > 90% field-level accuracy |
| Regulatory compliance | 100% on-time submission rate within 7/15-day deadlines |
| Touchless processing | 40–60% of non-serious cases processed without human intervention |
| Signal detection improvement | 20% improvement in signal detection accuracy |
| Case prioritization | 45% improvement in triage prioritization accuracy |

## Stakeholders

| Role | Interest |
|------|----------|
| VP Drug Safety / QPPV | Regulatory compliance, on-time submissions, liability reduction |
| PV Operations Manager | Reduce manual workload, handle volume spikes, lower overtime costs |
| Medical Safety Officer | Accurate causality assessment, reliable signal detection |
| IT / Platform Engineering | System integration, data security, validation (GxP/CSV) |
| Regulatory Affairs | ICH E2B(R3) compliance, inspection readiness |
| Quality Assurance | Audit trails, SOPs, change control for AI systems |
| Chief Financial Officer | Reduce per-product PV cost, avoid regulatory fines |

## Constraints

| Constraint | Detail |
|-----------|--------|
| **Data Privacy** | Patient PII and PHI in every report. GDPR (EU), HIPAA-adjacent sensitivity (US), and country-specific data residency requirements. |
| **Latency** | Near-real-time for triage (24-hour regulatory clock). Batch acceptable for literature screening. Submission deadlines are hard. |
| **Budget** | Must demonstrate ROI within 12–18 months. Cloud compute costs must stay below current FTE cost savings. |
| **Existing Systems** | Must integrate with incumbent safety databases — Oracle Argus Safety, Veeva Vault Safety, or ArisGlobal LifeSphere. |
| **Compliance** | GxP / Computer System Validation (CSV) requirements. FDA E2B(R3) electronic submission deadline: April 1, 2026. |
| **Scale** | Must handle 2,000–50,000+ cases/month. Must absorb 3–5x volume spikes. |

## Scope Boundaries

### In Scope

- Automated intake and triage of adverse event reports from structured and unstructured sources
- AI-assisted MedDRA and WHO Drug Dictionary coding
- Automated duplicate detection across the case database
- AI-generated clinical narratives with human review
- Touchless processing pipeline for routine non-serious cases
- Integration with one major safety database (Oracle Argus, Veeva Vault Safety, or LifeSphere)
- Regulatory submission formatting (ICH E2B(R3))
- Human-in-the-loop workflows for serious cases and causality override

### Out of Scope

- Safety signal detection and evaluation (separate analytical function)
- Benefit-risk assessment and regulatory decision-making
- Clinical trial safety reporting (separate SUSAR workflow)
- Social media and web scraping for AE detection (upstream data acquisition)
- Replacement of the safety database platform itself
- Regulatory authority interaction and query response handling
